Companies / United Arab Emirates
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Resource Constraints Threaten Julphar's Expansion
January 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
In December 2007, BMI commented on the ambitious domestic expansion plans of the UAE's largest drugmaker, Julphar (Gulf Pharmaceutical Industries), noting that the country should prove an attractive production base. We maintain our view that a company sales target of AED2.25bn (US$613mn) by 2010 is an achievable. Growing domestic wealth should boost domestic sales, while increased Gulf Co-Operation Council (GCC) integration and a proposed free trade agreement (FTA) with the US should drive Julphar's revenues abroad. However, resource constraints are increasingly evident in the UAE, and here BMI considers how these could affect Julphar's domestic manufacturing